Read More

Why Is Itch-Focused Cara Therapeutics Stock Trading Lower Today?

Cara Therapeutics Inc (NASDAQ: CARA) announced the outcome from the dose-finding Part A of the KIND 1 study evaluating the efficacy and safety of oral difelikefalin as adjunct therapy to topical corticosteroids (TCS) for moderate-to-severe pruritus in adult patients with 

CARA

Read More

iDoseTR Approval Sets Stage for Glaukos’ Game-Changing Product, Surpassing Market Expectations, Says Analyst

Thursday, the FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure in patients with ocular hypertension 

GKOS